These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36209558)

  • 21. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
    Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
    Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
    Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R;
    World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study.
    Wilens TE; Biederman J; Lerner M;
    J Clin Psychopharmacol; 2004 Feb; 24(1):36-41. PubMed ID: 14709945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
    J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
    [No Abstract]   [Full Text] [Related]  

  • 25. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status.
    Huang YS; Wang LJ; Chen CK
    BMC Psychiatry; 2012 Nov; 12():194. PubMed ID: 23140464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levels of Proneness to Boredom in Children with Attention-Deficit/Hyperactivity Disorder On and Off Methylphenidate Treatment.
    Golubchik P; Manor I; Shoval G; Weizman A
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):173-176. PubMed ID: 32031873
    [No Abstract]   [Full Text] [Related]  

  • 31. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Gillies D; Leach MJ; Perez Algorta G
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
    Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
    J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
    [No Abstract]   [Full Text] [Related]  

  • 33. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
    Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Tolerability of Methylphenidate in Treatment-Naïve Children with ADHD: An Analysis of Naturalistically Collected Data from Clinical Practice.
    Masi G; Pfanner C; Liboni F; Lenzi F; Villafranca A; D'Acunto G; Fantozzi P; Falcone F; Simonelli V; Muratori P; Levantini V; Favole I; Amianto F; Davico C; Vitiello B
    Paediatr Drugs; 2022 Mar; 24(2):147-154. PubMed ID: 35137333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term methylphenidate use for children and adolescents with attention deficit hyperactivity disorder and risk for depression, conduct disorder, and psychotic disorder: a nationwide longitudinal cohort study in South Korea.
    Park J; Lee DY; Kim C; Lee YH; Yang SJ; Lee S; Kim SJ; Lee J; Park RW; Shin Y
    Child Adolesc Psychiatry Ment Health; 2022 Oct; 16(1):80. PubMed ID: 36221129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.
    Winhusen TM; Lewis DF; Riggs PD; Davies RD; Adler LA; Sonne S; Somoza EC
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):455-63. PubMed ID: 22040190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.